MedTrace Logo

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

NCT04770012 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-05-06

No results posted yet for this study

Summary

Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

Conditions

  • Cardiac Allograft Vasculopathy
  • Heart Transplant

Interventions

DRUG

Placebo

patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment

DRUG

aspirin

patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment

DRUG

Clopidogrel

patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Sharon Chih · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2027-03-31
Completion
2029-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770012 on ClinicalTrials.gov